Capricor Therapeutics (CAPR) Return on Sales (2011 - 2025)

Capricor Therapeutics' Return on Sales history runs 15 years deep, the most recent figure standing at 0.16% for Q3 2025.

• On a quarterly basis, Return on Sales rose 42.0% year-over-year to 0.16% in Q3 2025; TTM through Sep 2025 was 0.16%, a 9.0% decrease from a year earlier, with the FY2024 full-year figure at 0.02%, changed 0.0% from the prior year.
• Return on Sales rose to 0.16% in Q3 2025 per CAPR's latest filing, from 0.19% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2023 and bottomed at 1.26% in Q1 2021.
• The 5-year median for Return on Sales is 0.11% (2025), against an average of 0.29%.
• Biggest YoY gain for Return on Sales was 630 bps in 2021; the steepest drop was 115 bps in 2021.
• Year by year, Return on Sales stood at 1.08% in 2021, then soared by 93 bps to 0.08% in 2022, then jumped by 99 bps to 0.0% in 2023, then tumbled by 476 bps to 0.01% in 2024, then sank by 2395 bps to 0.16% in 2025.
• Per Business Quant, the three latest CAPR Return on Sales figures stand at 0.16% (Q3 2025), 0.19% (Q2 2025), and 0.11% (Q1 2025).